Skip to main content

Advertisement

Table 1 Clinical and laboratory data from acute lymphoblastic leukemia patients

From: Increased levels of cyclin D1 negatively impacts on acute lymphoblastic leukemia overall survival

Characteristics Total patients (n = 45) Cyclin D1 a p-value
Low expression (n = 20) High expression (n = 20)
Age, years; median (range) 27 (18–79) 22 (18–67) 38 (18–79) 0.022
Gender
 Male, n (%) 30 (66.7) 14 (70) 13 (65)  
 Female, n (%) 15 (33.3) 6 (30) 7 (35) 0.49
Immunophenotype
 B-ALL, n (%) 35 (79.5) 14 (70) 18 (90) 0.114
 T-ALL, n (%) 9 (20.5) 6 (30) 2 (10)
BCR-ABL1 positive, n (%)
 Positive, n (%) 10 (22.2) 1 (5) 7 (35)  
 Negative, n (%) 35 (77.8) 19 (95) 13 (65) 0.018
Peripheral blood counts, median (range)
 Hemoglobin, g/dL 9.1 (5.2–15.8) 7.9 (5.2–15.2) 9.3 (5.3–15.8) 0.235
 WBC, × 109/L 12.2 (0.8–549.5) 23.8 (3.2–549.5) 8.2 (0.8–61.8) 0.013
 Platelets, × 109/L 38 (4–433) 29 (4–162) 38 (7–433) 0.419
LDH, median (range); U/L 1440 (245–13090) 2625 (270–13090) 1410 (245–6848) 0.09
  1. Abbreviations: ALL acute lymphoblastic leukemia, T-ALL precursor T-acute lymphoblastic leukemia, B-ALL precursor B-acute lymphoblastic leukemia, BCR-ABL1 breakpoint cluster region-abelson 1, WBC white blood cell, LDH lactic dehydrogenase
  2. aPatients with ALL whose sample were collected at diagnosis (n = 40) were included in the analysis
  3. Statistically significant p values are highlighted in bold